nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—CYP1A2—Carmustine—brain cancer	0.106	0.771	CbGbCtD
Phenylpropanolamine—DRD1—telencephalic ventricle—brain cancer	0.0423	0.0897	CbGeAlD
Phenylpropanolamine—SLC6A3—telencephalic ventricle—brain cancer	0.034	0.0721	CbGeAlD
Phenylpropanolamine—CYP1A2—Etoposide—brain cancer	0.0315	0.229	CbGbCtD
Phenylpropanolamine—DRD1—ganglion—brain cancer	0.0264	0.0558	CbGeAlD
Phenylpropanolamine—SLC6A3—ganglion—brain cancer	0.0212	0.0449	CbGeAlD
Phenylpropanolamine—SLC6A2—ganglion—brain cancer	0.0171	0.0362	CbGeAlD
Phenylpropanolamine—SLC6A3—hindbrain—brain cancer	0.0161	0.034	CbGeAlD
Phenylpropanolamine—MAOA—ganglion—brain cancer	0.0157	0.0333	CbGeAlD
Phenylpropanolamine—Pseudoephedrine—IL2—brain cancer	0.0145	0.514	CrCbGaD
Phenylpropanolamine—Ataxia—Lomustine—brain cancer	0.0126	0.0425	CcSEcCtD
Phenylpropanolamine—ADRA1A—hindbrain—brain cancer	0.012	0.0255	CbGeAlD
Phenylpropanolamine—MAOA—hindbrain—brain cancer	0.0119	0.0253	CbGeAlD
Phenylpropanolamine—DRD1—brainstem—brain cancer	0.0115	0.0243	CbGeAlD
Phenylpropanolamine—DRD1—telencephalon—brain cancer	0.0102	0.0215	CbGeAlD
Phenylpropanolamine—SLC6A3—brainstem—brain cancer	0.00921	0.0195	CbGeAlD
Phenylpropanolamine—Liver injury—Temozolomide—brain cancer	0.00842	0.0284	CcSEcCtD
Phenylpropanolamine—SLC6A3—telencephalon—brain cancer	0.00817	0.0173	CbGeAlD
Phenylpropanolamine—Ataxia—Procarbazine—brain cancer	0.008	0.027	CcSEcCtD
Phenylpropanolamine—ADRB1—telencephalon—brain cancer	0.00775	0.0164	CbGeAlD
Phenylpropanolamine—Coordination abnormal—Carmustine—brain cancer	0.00746	0.0252	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP2C9—brain cancer	0.00746	0.264	CrCbGaD
Phenylpropanolamine—SLC6A2—brainstem—brain cancer	0.00743	0.0157	CbGeAlD
Phenylpropanolamine—DRD1—midbrain—brain cancer	0.0073	0.0155	CbGeAlD
Phenylpropanolamine—Coordination abnormal—Temozolomide—brain cancer	0.00721	0.0243	CcSEcCtD
Phenylpropanolamine—ADRA1A—brainstem—brain cancer	0.00691	0.0146	CbGeAlD
Phenylpropanolamine—MAOA—brainstem—brain cancer	0.00684	0.0145	CbGeAlD
Phenylpropanolamine—SLC6A2—telencephalon—brain cancer	0.00659	0.014	CbGeAlD
Phenylpropanolamine—Drowsiness—Procarbazine—brain cancer	0.00655	0.0221	CcSEcCtD
Phenylpropanolamine—DRD1—head—brain cancer	0.00633	0.0134	CbGeAlD
Phenylpropanolamine—Phentermine—CYP2C9—brain cancer	0.00625	0.222	CrCbGaD
Phenylpropanolamine—ADRA1A—telencephalon—brain cancer	0.00613	0.013	CbGeAlD
Phenylpropanolamine—MAOA—telencephalon—brain cancer	0.00607	0.0129	CbGeAlD
Phenylpropanolamine—SLC6A3—midbrain—brain cancer	0.00587	0.0124	CbGeAlD
Phenylpropanolamine—Hallucination—Procarbazine—brain cancer	0.00585	0.0197	CcSEcCtD
Phenylpropanolamine—DRD1—central nervous system—brain cancer	0.00578	0.0122	CbGeAlD
Phenylpropanolamine—SLC6A3—spinal cord—brain cancer	0.00573	0.0121	CbGeAlD
Phenylpropanolamine—SLC6A2—gonad—brain cancer	0.0055	0.0117	CbGeAlD
Phenylpropanolamine—Flushing—Procarbazine—brain cancer	0.00546	0.0184	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Procarbazine—brain cancer	0.00526	0.0177	CcSEcCtD
Phenylpropanolamine—SLC6A2—medulla oblongata—brain cancer	0.00518	0.011	CbGeAlD
Phenylpropanolamine—SLC6A3—head—brain cancer	0.00509	0.0108	CbGeAlD
Phenylpropanolamine—Drowsiness—Hydroxyurea—brain cancer	0.00507	0.0171	CcSEcCtD
Phenylpropanolamine—Tension—Procarbazine—brain cancer	0.00503	0.017	CcSEcCtD
Phenylpropanolamine—Ataxia—Carmustine—brain cancer	0.005	0.0169	CcSEcCtD
Phenylpropanolamine—Nervousness—Procarbazine—brain cancer	0.00497	0.0168	CcSEcCtD
Phenylpropanolamine—MAOA—pituitary gland—brain cancer	0.00495	0.0105	CbGeAlD
Phenylpropanolamine—ADRB1—endocrine gland—brain cancer	0.00489	0.0104	CbGeAlD
Phenylpropanolamine—Ataxia—Temozolomide—brain cancer	0.00483	0.0163	CcSEcCtD
Phenylpropanolamine—ADRB1—head—brain cancer	0.00483	0.0102	CbGeAlD
Phenylpropanolamine—Tremor—Procarbazine—brain cancer	0.0048	0.0162	CcSEcCtD
Phenylpropanolamine—MAOA—medulla oblongata—brain cancer	0.00477	0.0101	CbGeAlD
Phenylpropanolamine—ADRA2A—telencephalon—brain cancer	0.00466	0.00987	CbGeAlD
Phenylpropanolamine—SLC6A3—central nervous system—brain cancer	0.00464	0.00984	CbGeAlD
Phenylpropanolamine—DRD1—brain—brain cancer	0.00459	0.00972	CbGeAlD
Phenylpropanolamine—SLC6A3—cerebellum—brain cancer	0.00454	0.00961	CbGeAlD
Phenylpropanolamine—Hallucination—Hydroxyurea—brain cancer	0.00453	0.0153	CcSEcCtD
Phenylpropanolamine—ADRB1—central nervous system—brain cancer	0.00441	0.00933	CbGeAlD
Phenylpropanolamine—MAOA—midbrain—brain cancer	0.00436	0.00924	CbGeAlD
Phenylpropanolamine—Anxiety—Procarbazine—brain cancer	0.00435	0.0147	CcSEcCtD
Phenylpropanolamine—MAOA—spinal cord—brain cancer	0.00426	0.00901	CbGeAlD
Phenylpropanolamine—Confusional state—Procarbazine—brain cancer	0.00421	0.0142	CcSEcCtD
Phenylpropanolamine—Vomiting—Lomustine—brain cancer	0.00419	0.0141	CcSEcCtD
Phenylpropanolamine—SLC6A2—endocrine gland—brain cancer	0.00416	0.00881	CbGeAlD
Phenylpropanolamine—SLC6A2—head—brain cancer	0.00411	0.00869	CbGeAlD
Phenylpropanolamine—Tachycardia—Procarbazine—brain cancer	0.00408	0.0138	CcSEcCtD
Phenylpropanolamine—Nausea—Lomustine—brain cancer	0.00391	0.0132	CcSEcCtD
Phenylpropanolamine—Hypotension—Procarbazine—brain cancer	0.00391	0.0132	CcSEcCtD
Phenylpropanolamine—ADRA2A—gonad—brain cancer	0.00389	0.00824	CbGeAlD
Phenylpropanolamine—ADRA1A—endocrine gland—brain cancer	0.00387	0.00819	CbGeAlD
Phenylpropanolamine—MAOA—endocrine gland—brain cancer	0.00383	0.00811	CbGeAlD
Phenylpropanolamine—ADRA1A—head—brain cancer	0.00382	0.00808	CbGeAlD
Phenylpropanolamine—ADRA2A—pituitary gland—brain cancer	0.00379	0.00804	CbGeAlD
Phenylpropanolamine—MAOA—head—brain cancer	0.00378	0.00801	CbGeAlD
Phenylpropanolamine—Insomnia—Procarbazine—brain cancer	0.00378	0.0128	CcSEcCtD
Phenylpropanolamine—SLC6A2—central nervous system—brain cancer	0.00375	0.00794	CbGeAlD
Phenylpropanolamine—Somnolence—Procarbazine—brain cancer	0.00372	0.0125	CcSEcCtD
Phenylpropanolamine—SLC6A3—brain—brain cancer	0.00369	0.00781	CbGeAlD
Phenylpropanolamine—Hallucination—Carmustine—brain cancer	0.00366	0.0124	CcSEcCtD
Phenylpropanolamine—ADRA2A—medulla oblongata—brain cancer	0.00366	0.00775	CbGeAlD
Phenylpropanolamine—Constipation—Procarbazine—brain cancer	0.00357	0.0121	CcSEcCtD
Phenylpropanolamine—Hallucination—Temozolomide—brain cancer	0.00354	0.0119	CcSEcCtD
Phenylpropanolamine—ADRB1—brain—brain cancer	0.0035	0.00741	CbGeAlD
Phenylpropanolamine—ADRA1A—central nervous system—brain cancer	0.00348	0.00738	CbGeAlD
Phenylpropanolamine—MAOA—central nervous system—brain cancer	0.00345	0.00731	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Procarbazine—brain cancer	0.00344	0.0116	CcSEcCtD
Phenylpropanolamine—Flushing—Carmustine—brain cancer	0.00342	0.0115	CcSEcCtD
Phenylpropanolamine—ADRA1A—cerebellum—brain cancer	0.0034	0.00721	CbGeAlD
Phenylpropanolamine—MAOA—cerebellum—brain cancer	0.00337	0.00715	CbGeAlD
Phenylpropanolamine—ADRA2A—midbrain—brain cancer	0.00335	0.00709	CbGeAlD
Phenylpropanolamine—Flushing—Temozolomide—brain cancer	0.0033	0.0111	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Carmustine—brain cancer	0.00329	0.0111	CcSEcCtD
Phenylpropanolamine—ADRA2A—spinal cord—brain cancer	0.00327	0.00691	CbGeAlD
Phenylpropanolamine—CYP1A2—endocrine gland—brain cancer	0.0032	0.00677	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Procarbazine—brain cancer	0.00308	0.0104	CcSEcCtD
Phenylpropanolamine—Vision blurred—Carmustine—brain cancer	0.00302	0.0102	CcSEcCtD
Phenylpropanolamine—Tremor—Carmustine—brain cancer	0.003	0.0101	CcSEcCtD
Phenylpropanolamine—SLC6A2—brain—brain cancer	0.00297	0.0063	CbGeAlD
Phenylpropanolamine—Agitation—Carmustine—brain cancer	0.00294	0.00993	CcSEcCtD
Phenylpropanolamine—ADRA2A—endocrine gland—brain cancer	0.00294	0.00623	CbGeAlD
Phenylpropanolamine—Vision blurred—Temozolomide—brain cancer	0.00292	0.00984	CcSEcCtD
Phenylpropanolamine—ADRA2A—head—brain cancer	0.0029	0.00615	CbGeAlD
Phenylpropanolamine—Tremor—Temozolomide—brain cancer	0.0029	0.00979	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Hydroxyurea—brain cancer	0.00288	0.00973	CcSEcCtD
Phenylpropanolamine—Somnolence—Hydroxyurea—brain cancer	0.00288	0.0097	CcSEcCtD
Phenylpropanolamine—Agitation—Temozolomide—brain cancer	0.00285	0.0096	CcSEcCtD
Phenylpropanolamine—Constipation—Hydroxyurea—brain cancer	0.00277	0.00933	CcSEcCtD
Phenylpropanolamine—ADRA1A—brain—brain cancer	0.00277	0.00586	CbGeAlD
Phenylpropanolamine—Dizziness—Procarbazine—brain cancer	0.00276	0.00932	CcSEcCtD
Phenylpropanolamine—MAOA—brain—brain cancer	0.00274	0.0058	CbGeAlD
Phenylpropanolamine—Anxiety—Carmustine—brain cancer	0.00272	0.00917	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Hydroxyurea—brain cancer	0.00267	0.00899	CcSEcCtD
Phenylpropanolamine—Vomiting—Procarbazine—brain cancer	0.00266	0.00896	CcSEcCtD
Phenylpropanolamine—ADRA2A—central nervous system—brain cancer	0.00265	0.00561	CbGeAlD
Phenylpropanolamine—Flushing—Etoposide—brain cancer	0.00264	0.00891	CcSEcCtD
Phenylpropanolamine—Confusional state—Carmustine—brain cancer	0.00264	0.00889	CcSEcCtD
Phenylpropanolamine—Rash—Procarbazine—brain cancer	0.00264	0.00889	CcSEcCtD
Phenylpropanolamine—Dermatitis—Procarbazine—brain cancer	0.00263	0.00888	CcSEcCtD
Phenylpropanolamine—Anxiety—Temozolomide—brain cancer	0.00263	0.00886	CcSEcCtD
Phenylpropanolamine—ADRA2A—cerebellum—brain cancer	0.00259	0.00548	CbGeAlD
Phenylpropanolamine—Tachycardia—Carmustine—brain cancer	0.00255	0.00861	CcSEcCtD
Phenylpropanolamine—Confusional state—Temozolomide—brain cancer	0.00255	0.0086	CcSEcCtD
Phenylpropanolamine—Nausea—Procarbazine—brain cancer	0.00248	0.00837	CcSEcCtD
Phenylpropanolamine—Hypotension—Carmustine—brain cancer	0.00244	0.00824	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Hydroxyurea—brain cancer	0.00238	0.00804	CcSEcCtD
Phenylpropanolamine—Insomnia—Carmustine—brain cancer	0.00237	0.00798	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Carmustine—brain cancer	0.00233	0.00786	CcSEcCtD
Phenylpropanolamine—Somnolence—Carmustine—brain cancer	0.00232	0.00784	CcSEcCtD
Phenylpropanolamine—Insomnia—Temozolomide—brain cancer	0.00229	0.00771	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Temozolomide—brain cancer	0.00225	0.0076	CcSEcCtD
Phenylpropanolamine—Somnolence—Temozolomide—brain cancer	0.00225	0.00758	CcSEcCtD
Phenylpropanolamine—Constipation—Carmustine—brain cancer	0.00224	0.00754	CcSEcCtD
Phenylpropanolamine—Constipation—Temozolomide—brain cancer	0.00216	0.00729	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Carmustine—brain cancer	0.00215	0.00727	CcSEcCtD
Phenylpropanolamine—Dizziness—Hydroxyurea—brain cancer	0.00214	0.00722	CcSEcCtD
Phenylpropanolamine—ADRA2A—brain—brain cancer	0.0021	0.00445	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Temozolomide—brain cancer	0.00208	0.00702	CcSEcCtD
Phenylpropanolamine—Vomiting—Hydroxyurea—brain cancer	0.00206	0.00694	CcSEcCtD
Phenylpropanolamine—Rash—Hydroxyurea—brain cancer	0.00204	0.00688	CcSEcCtD
Phenylpropanolamine—Confusional state—Etoposide—brain cancer	0.00204	0.00688	CcSEcCtD
Phenylpropanolamine—Dermatitis—Hydroxyurea—brain cancer	0.00204	0.00687	CcSEcCtD
Phenylpropanolamine—Tachycardia—Etoposide—brain cancer	0.00197	0.00666	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Carmustine—brain cancer	0.00193	0.0065	CcSEcCtD
Phenylpropanolamine—Nausea—Hydroxyurea—brain cancer	0.00192	0.00648	CcSEcCtD
Phenylpropanolamine—Hypotension—Etoposide—brain cancer	0.00189	0.00637	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Temozolomide—brain cancer	0.00186	0.00628	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Etoposide—brain cancer	0.0018	0.00608	CcSEcCtD
Phenylpropanolamine—Somnolence—Etoposide—brain cancer	0.0018	0.00606	CcSEcCtD
Phenylpropanolamine—Dizziness—Carmustine—brain cancer	0.00173	0.00583	CcSEcCtD
Phenylpropanolamine—Constipation—Etoposide—brain cancer	0.00173	0.00583	CcSEcCtD
Phenylpropanolamine—Dizziness—Temozolomide—brain cancer	0.00167	0.00564	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Etoposide—brain cancer	0.00167	0.00562	CcSEcCtD
Phenylpropanolamine—Vomiting—Carmustine—brain cancer	0.00166	0.00561	CcSEcCtD
Phenylpropanolamine—Rash—Carmustine—brain cancer	0.00165	0.00556	CcSEcCtD
Phenylpropanolamine—Dermatitis—Carmustine—brain cancer	0.00165	0.00556	CcSEcCtD
Phenylpropanolamine—Vomiting—Temozolomide—brain cancer	0.00161	0.00542	CcSEcCtD
Phenylpropanolamine—Rash—Temozolomide—brain cancer	0.00159	0.00537	CcSEcCtD
Phenylpropanolamine—Dermatitis—Temozolomide—brain cancer	0.00159	0.00537	CcSEcCtD
Phenylpropanolamine—Nausea—Carmustine—brain cancer	0.00155	0.00524	CcSEcCtD
Phenylpropanolamine—Nausea—Temozolomide—brain cancer	0.0015	0.00506	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Etoposide—brain cancer	0.00149	0.00503	CcSEcCtD
Phenylpropanolamine—Dizziness—Etoposide—brain cancer	0.00134	0.00451	CcSEcCtD
Phenylpropanolamine—Vomiting—Etoposide—brain cancer	0.00129	0.00434	CcSEcCtD
Phenylpropanolamine—Rash—Etoposide—brain cancer	0.00128	0.0043	CcSEcCtD
Phenylpropanolamine—Dermatitis—Etoposide—brain cancer	0.00127	0.0043	CcSEcCtD
Phenylpropanolamine—Nausea—Etoposide—brain cancer	0.0012	0.00405	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DTX2—brain cancer	0.000107	0.00164	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	0.000106	0.00163	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	0.000106	0.00163	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STRADA—brain cancer	0.000105	0.0016	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—TRPC6—brain cancer	0.000103	0.00158	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—BSG—brain cancer	0.000102	0.00156	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	0.000102	0.00156	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTCH2—brain cancer	0.0001	0.00153	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—ABR—brain cancer	9.99e-05	0.00153	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	9.94e-05	0.00152	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DTX2—brain cancer	9.93e-05	0.00152	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTCH2—brain cancer	9.79e-05	0.0015	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—SHH—brain cancer	9.71e-05	0.00149	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HES5—brain cancer	9.69e-05	0.00148	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HES5—brain cancer	9.48e-05	0.00145	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STRADA—brain cancer	9.41e-05	0.00144	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—TRPC6—brain cancer	9.36e-05	0.00143	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—TRPC6—brain cancer	9.27e-05	0.00142	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STRADA—brain cancer	9.2e-05	0.00141	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PTCH1—brain cancer	9.2e-05	0.00141	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—SMO—brain cancer	9.2e-05	0.00141	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—TRPC6—brain cancer	9.07e-05	0.00139	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—IDH1—brain cancer	8.78e-05	0.00134	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ABR—brain cancer	8.74e-05	0.00134	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—SHH—brain cancer	8.73e-05	0.00134	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—SHH—brain cancer	8.54e-05	0.00131	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—GLI2—brain cancer	8.44e-05	0.00129	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—TRPC6—brain cancer	8.42e-05	0.00129	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PTCH1—brain cancer	8.27e-05	0.00127	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—SMO—brain cancer	8.27e-05	0.00127	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—VAV1—brain cancer	8.26e-05	0.00127	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—TRPC6—brain cancer	8.23e-05	0.00126	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTCH2—brain cancer	8.1e-05	0.00124	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PTCH1—brain cancer	8.09e-05	0.00124	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—SMO—brain cancer	8.09e-05	0.00124	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CYP2C9—brain cancer	8.02e-05	0.00123	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—GLI1—brain cancer	7.93e-05	0.00121	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ABR—brain cancer	7.85e-05	0.0012	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HES5—brain cancer	7.84e-05	0.0012	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—VAV1—brain cancer	7.72e-05	0.00118	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ABR—brain cancer	7.68e-05	0.00118	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STRADA—brain cancer	7.61e-05	0.00117	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GLI2—brain cancer	7.58e-05	0.00116	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTCH2—brain cancer	7.52e-05	0.00115	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SUFU—brain cancer	7.52e-05	0.00115	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—TRPC6—brain cancer	7.5e-05	0.00115	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GLI2—brain cancer	7.42e-05	0.00114	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—TP53—brain cancer	7.34e-05	0.00112	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HES5—brain cancer	7.29e-05	0.00112	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	7.27e-05	0.00111	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—GFAP—brain cancer	7.25e-05	0.00111	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—IL2—brain cancer	7.16e-05	0.0011	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GLI1—brain cancer	7.13e-05	0.00109	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STRADA—brain cancer	7.07e-05	0.00108	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—SHH—brain cancer	7.06e-05	0.00108	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—VAV1—brain cancer	7.01e-05	0.00107	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GLI1—brain cancer	6.98e-05	0.00107	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—TRPC6—brain cancer	6.97e-05	0.00107	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—VAV1—brain cancer	6.94e-05	0.00106	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ENO2—brain cancer	6.94e-05	0.00106	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HEY1—brain cancer	6.88e-05	0.00105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—BSG—brain cancer	6.82e-05	0.00104	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—TRPC6—brain cancer	6.81e-05	0.00104	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—VAV1—brain cancer	6.79e-05	0.00104	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SUFU—brain cancer	6.76e-05	0.00104	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DLL1—brain cancer	6.74e-05	0.00103	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PTCH1—brain cancer	6.69e-05	0.00103	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—SMO—brain cancer	6.69e-05	0.00103	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SUFU—brain cancer	6.61e-05	0.00101	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—SHH—brain cancer	6.56e-05	0.001	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GFAP—brain cancer	6.52e-05	0.000999	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GFAP—brain cancer	6.38e-05	0.000977	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ABR—brain cancer	6.35e-05	0.000973	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—TRPC6—brain cancer	6.33e-05	0.000969	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—VAV1—brain cancer	6.31e-05	0.000966	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PTCH1—brain cancer	6.22e-05	0.000953	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—SMO—brain cancer	6.22e-05	0.000953	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HEY1—brain cancer	6.18e-05	0.000947	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—VAV1—brain cancer	6.17e-05	0.000945	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GLI2—brain cancer	6.14e-05	0.00094	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—brain cancer	6.09e-05	0.000932	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DLL1—brain cancer	6.06e-05	0.000929	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HEY1—brain cancer	6.05e-05	0.000926	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	6.03e-05	0.000923	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DLL1—brain cancer	5.93e-05	0.000908	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ABR—brain cancer	5.9e-05	0.000904	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—IDH1—brain cancer	5.86e-05	0.000898	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GLI1—brain cancer	5.77e-05	0.000884	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SHH—brain cancer	5.73e-05	0.000878	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GLI2—brain cancer	5.7e-05	0.000873	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—VAV1—brain cancer	5.62e-05	0.00086	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TRPC6—brain cancer	5.53e-05	0.000847	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SUFU—brain cancer	5.47e-05	0.000838	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTCH1—brain cancer	5.44e-05	0.000833	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SMO—brain cancer	5.44e-05	0.000833	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GLI1—brain cancer	5.36e-05	0.000821	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GFAP—brain cancer	5.28e-05	0.000808	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—PIK3CG—brain cancer	5.24e-05	0.000803	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—VAV1—brain cancer	5.22e-05	0.000799	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SHH—brain cancer	5.16e-05	0.00079	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—VAV1—brain cancer	5.1e-05	0.000781	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SUFU—brain cancer	5.08e-05	0.000778	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SHH—brain cancer	5.04e-05	0.000772	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HEY1—brain cancer	5e-05	0.000766	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TRPC6—brain cancer	4.97e-05	0.000761	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DLL1—brain cancer	4.91e-05	0.000751	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—PIK3CG—brain cancer	4.9e-05	0.000751	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GFAP—brain cancer	4.9e-05	0.000751	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTCH1—brain cancer	4.89e-05	0.000749	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SMO—brain cancer	4.89e-05	0.000749	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TRPC6—brain cancer	4.86e-05	0.000745	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTCH1—brain cancer	4.78e-05	0.000732	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SMO—brain cancer	4.78e-05	0.000732	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—VAV1—brain cancer	4.74e-05	0.000726	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HEY1—brain cancer	4.65e-05	0.000712	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ENO2—brain cancer	4.64e-05	0.00071	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DLL1—brain cancer	4.56e-05	0.000698	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PIK3CG—brain cancer	4.45e-05	0.000682	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP2C9—brain cancer	4.43e-05	0.000678	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—PIK3CG—brain cancer	4.41e-05	0.000675	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NOTCH2—brain cancer	4.35e-05	0.000666	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—PIK3CG—brain cancer	4.31e-05	0.000661	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SHH—brain cancer	4.17e-05	0.000639	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VAV1—brain cancer	4.14e-05	0.000635	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TRPC6—brain cancer	4.02e-05	0.000616	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PIK3CG—brain cancer	4e-05	0.000613	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTCH1—brain cancer	3.95e-05	0.000606	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SMO—brain cancer	3.95e-05	0.000606	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PIK3CG—brain cancer	3.92e-05	0.0006	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NOTCH2—brain cancer	3.91e-05	0.000598	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SHH—brain cancer	3.88e-05	0.000594	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NOTCH2—brain cancer	3.82e-05	0.000585	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—BSG—brain cancer	3.76e-05	0.000577	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TRPC6—brain cancer	3.74e-05	0.000572	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VAV1—brain cancer	3.72e-05	0.00057	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—IL2—brain cancer	3.69e-05	0.000565	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTCH1—brain cancer	3.67e-05	0.000563	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SMO—brain cancer	3.67e-05	0.000563	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VAV1—brain cancer	3.64e-05	0.000558	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PIK3CG—brain cancer	3.57e-05	0.000546	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HES1—brain cancer	3.56e-05	0.000546	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—IL2—brain cancer	3.45e-05	0.000529	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PDGFRA—brain cancer	3.39e-05	0.00052	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CG—brain cancer	3.31e-05	0.000508	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SPP1—brain cancer	3.29e-05	0.000504	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CG—brain cancer	3.24e-05	0.000496	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—IDH1—brain cancer	3.24e-05	0.000496	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HES1—brain cancer	3.2e-05	0.000491	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CG—brain cancer	3.18e-05	0.000487	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOTCH2—brain cancer	3.16e-05	0.000484	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—VEGFA—brain cancer	3.14e-05	0.00048	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL2—brain cancer	3.13e-05	0.00048	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HES1—brain cancer	3.13e-05	0.00048	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—IL2—brain cancer	3.1e-05	0.000475	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PDGFRA—brain cancer	3.05e-05	0.000467	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—IL2—brain cancer	3.04e-05	0.000465	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VAV1—brain cancer	3.01e-05	0.000462	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CG—brain cancer	3.01e-05	0.000461	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PDGFRA—brain cancer	2.98e-05	0.000457	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IRS2—brain cancer	2.98e-05	0.000456	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SPP1—brain cancer	2.96e-05	0.000454	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOTCH2—brain cancer	2.94e-05	0.00045	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SPP1—brain cancer	2.9e-05	0.000444	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL2—brain cancer	2.82e-05	0.000432	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VAV1—brain cancer	2.8e-05	0.000429	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL2—brain cancer	2.76e-05	0.000422	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IRS2—brain cancer	2.68e-05	0.00041	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.64e-05	0.000404	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APC—brain cancer	2.63e-05	0.000403	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CG—brain cancer	2.63e-05	0.000403	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IRS2—brain cancer	2.62e-05	0.000401	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HES1—brain cancer	2.59e-05	0.000397	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ENO2—brain cancer	2.56e-05	0.000392	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—IL2—brain cancer	2.51e-05	0.000384	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PDGFRA—brain cancer	2.47e-05	0.000378	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HES1—brain cancer	2.41e-05	0.000369	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—EGFR—brain cancer	2.4e-05	0.000367	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SPP1—brain cancer	2.4e-05	0.000367	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TP53—brain cancer	2.37e-05	0.000363	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APC—brain cancer	2.37e-05	0.000362	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CG—brain cancer	2.37e-05	0.000362	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—IL2—brain cancer	2.33e-05	0.000357	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APC—brain cancer	2.31e-05	0.000354	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CG—brain cancer	2.31e-05	0.000354	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PDGFRA—brain cancer	2.29e-05	0.000351	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL2—brain cancer	2.28e-05	0.000349	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SPP1—brain cancer	2.23e-05	0.000341	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IRS2—brain cancer	2.17e-05	0.000332	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—EGFR—brain cancer	2.15e-05	0.00033	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CG—brain cancer	2.13e-05	0.000326	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL2—brain cancer	2.12e-05	0.000324	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—EGFR—brain cancer	2.11e-05	0.000323	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RELA—brain cancer	2.06e-05	0.000315	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ERBB2—brain cancer	2.04e-05	0.000313	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IRS2—brain cancer	2.01e-05	0.000308	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APC—brain cancer	1.91e-05	0.000293	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CG—brain cancer	1.91e-05	0.000293	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL2—brain cancer	1.85e-05	0.000284	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RELA—brain cancer	1.85e-05	0.000283	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ERBB2—brain cancer	1.84e-05	0.000281	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RELA—brain cancer	1.81e-05	0.000277	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCND1—brain cancer	1.8e-05	0.000276	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ERBB2—brain cancer	1.8e-05	0.000275	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CTNNB1—brain cancer	1.79e-05	0.000274	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APC—brain cancer	1.78e-05	0.000272	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CG—brain cancer	1.78e-05	0.000272	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—EGFR—brain cancer	1.74e-05	0.000267	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL2—brain cancer	1.66e-05	0.000255	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL2—brain cancer	1.63e-05	0.000249	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCND1—brain cancer	1.62e-05	0.000248	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—EGFR—brain cancer	1.62e-05	0.000248	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CTNNB1—brain cancer	1.61e-05	0.000246	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCND1—brain cancer	1.59e-05	0.000243	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—brain cancer	1.57e-05	0.000241	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CTNNB1—brain cancer	1.57e-05	0.000241	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STAT3—brain cancer	1.56e-05	0.000239	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RELA—brain cancer	1.5e-05	0.000229	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ERBB2—brain cancer	1.49e-05	0.000228	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—brain cancer	1.45e-05	0.000222	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EGFR—brain cancer	1.42e-05	0.000217	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—brain cancer	1.41e-05	0.000217	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STAT3—brain cancer	1.4e-05	0.000214	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RELA—brain cancer	1.39e-05	0.000213	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—brain cancer	1.38e-05	0.000212	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ERBB2—brain cancer	1.38e-05	0.000211	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STAT3—brain cancer	1.37e-05	0.00021	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL2—brain cancer	1.35e-05	0.000206	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCND1—brain cancer	1.31e-05	0.000201	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—brain cancer	1.3e-05	0.000199	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CTNNB1—brain cancer	1.3e-05	0.000199	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—brain cancer	1.27e-05	0.000195	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EGFR—brain cancer	1.27e-05	0.000195	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL2—brain cancer	1.25e-05	0.000192	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EGFR—brain cancer	1.25e-05	0.000191	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCND1—brain cancer	1.22e-05	0.000187	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CTNNB1—brain cancer	1.21e-05	0.000185	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—brain cancer	1.19e-05	0.000182	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CG—brain cancer	1.17e-05	0.00018	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—brain cancer	1.14e-05	0.000175	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STAT3—brain cancer	1.13e-05	0.000174	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—brain cancer	1.07e-05	0.000164	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—brain cancer	1.06e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—brain cancer	1.05e-05	0.000161	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STAT3—brain cancer	1.05e-05	0.000161	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—brain cancer	1.05e-05	0.00016	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGFR—brain cancer	1.03e-05	0.000158	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—brain cancer	9.78e-06	0.00015	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGFR—brain cancer	9.57e-06	0.000147	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—brain cancer	8.65e-06	0.000132	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—brain cancer	8.03e-06	0.000123	CbGpPWpGaD
